Clinical Trial 22566

• Overview

  Study Title:

  Creation of Patient-Derived Xenografts from Early-Stage Primary Cutaneous Melanomas

  Objective:

  The primary objective of this project is to intraoperatively procure fresh primary melanoma tissue and blood samples from patients with primary cutaneous melanoma undergoing wide local excision as part of standard of care. This tissue in its entirety will be used in the creation of patient-derived mouse xenografts for use in future research projects.

• Inclusion Criteria

  • Moffitt patients with a diagnosis of primary cutaneous melanoma (stages 0-III or T0-T4) who are TCC consented and will be undergoing surgical removal of their primary tumor tissue
  • Sufficient residual primary melanoma present to allow procurement of at least a 4 mm tumor sample without compromising resection or pathologic analysis requirements
  • Patients must be over 18 years of age
  • There are no gender or ethnicity requirements

• Exclusion Criteria

  • Acral, desmoplastic and Spitz melanoma histologic subtypes, metastatic sites
  • No available tumor tissue
  • Not TCC consented
  • Patients who have received neoadjuvant targeted therapy or immunotherapy prior to surgery.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.